Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials. (PubMed, J Dermatolog Treat) - Aug 29, 2026 - "For F-VASI50, they were superior to tacrolimus (RR 1.88, 95% CI 1.02-3.45) but not significantly different from dexamethasone (RR 2.17, 95% CI 0.95-4.94). JAK inhibitors are effective and well tolerated for vitiligo. Topical ruxolitinib is supported as a first-line option for limited facial disease; oral agents show promise but require longer-term safety data."
Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Vitiligo
|
|
Changxia Xiong; Chunxiao Bai; Guangshan Chen; Jingpeng Chen; Xingwu Duan; Yi Chen; Yongxiang Long; Ziyi Lin
|